SELZENTRY is a CCR5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only CCR5-tropic HIV-1, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
Copyright © 2009 Pfizer Inc. All rights reserved.
The information provided in this site is intended only for residents of the United States.
Contact Us Terms of Use Privacy Policy Site Map
The products discussed herein may have different product labeling in different countries.
